This report series examines quarterly trends in life sciences venture investment. Key findings for Q2 2022 include:
• The industry generated $8.8 billion in deal value across 362 deals in Q2, a material decline from Q1, as the public market decline and macroeconomic pressures continued.
• Median deal sizes remained flat from 2021 for all stages except Series A. Median pre-money valuations rose across the board. A smaller population of deals may account for some of this increase.
• Public market turmoil continued to create ripple effects across the industry, particularly for exit activity. IPO conditions remain unfavorable, and acquisition activity was subdued.
Please see full publication below for more information.